Dutasteride

Evidence Level: L5

Predicted Indications: 10

Dutasteride

Pharmacist Assessment Report

Dutasteride: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Dutasteride is a 5-alpha reductase inhibitor originally used to treat benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, but there are currently 0 clinical trials and 0 publications directly supporting this prediction, so the evidence rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Benign prostatic hyperplasia (source: TxGNN knowledge graph; no approved indication text is recorded in the ARTG data compiled for this report)
Predicted New Indication	Ambras type hypertrichosis universalis congenita
TxGNN Prediction Score	1.0000
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Dutasteride is generally known as a dual inhibitor of 5-alpha reductase types 1 and 2, which lowers dihydrotestosterone (DHT). Its efficacy in BPH is established, and its effect on hair follicles through DHT reduction is the only plausible bridge to hair-related conditions.

The link to the predicted indication is weak. Ambras syndrome is a rare congenital hypertrichosis caused by genomic rearrangements affecting TRPS1 expression, and it is not clearly androgen-driven. The prediction therefore appears to rest on a very high model score and a general anti-androgen effect on hair follicles, not on direct pharmacological or clinical evidence.

Other top-ranked predictions show a similar pattern:

Hair-related conditions (hypertrichosis, isolated genetic hair shaft abnormality, hypotrichosis simplex of the scalp, congenital hypotrichosis milia, familial isolated trichomegaly): mechanistically plausible only via hair-follicle biology. Most are not clearly DHT-dependent, and the direction of effect is uncertain. For generalised hypertrichosis, dutasteride could even be counterproductive.
Hypotrichosis simplex of the scalp is phenotypically similar to androgenetic alopecia, for which dutasteride has an off-label evidence base, but its genetic cause is not clearly DHT-dependent.
Diffuse alopecia areata is autoimmune (T-cell-mediated, JAK-STAT pathway) and not DHT-driven.
Structural or neurological conditions (malformation syndrome with odontal/periodontal component, Dandy-Walker malformation syndrome, migraine with brainstem aura): no plausible mechanistic link was identified, and these scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

No literature was retrieved for the top-ranked prediction (Ambras type hypertrichosis universalis congenita).

For context, one paper was retrieved for a lower-ranked prediction (diffuse alopecia areata). It concerns a different condition and is not evidence for dutasteride in alopecia areata:

PMID	Year	Type	Journal	Key Findings
41714473	2026	Review	American Journal of Clinical Dermatology	Narrative review of androgenetic alopecia in women, covering pathophysiology, clinical evaluation and treatments. It affects nearly 50% of women in their lifetime and is often underdiagnosed and undertreated.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 10095H	APO-Dutasteride	Capsule 500 micrograms	Not recorded in the data compiled for this report

Safety Considerations

Contraindications and disease associations (knowledge-graph derived, not label text): multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, liver disease, gallbladder disease, priapism, intraoperative floppy iris syndrome.
Reproductive safety: dutasteride is teratogenic in male fetuses, as it interferes with external genitalia development. This argues against use in congenital or paediatric settings.
Drug Interactions: 100 interactions were identified in total. The main ones rated Moderate are:
- Aprepitant
- Cimetidine
- Clarithromycin
- Clotrimazole
- Miconazole
Others, such as pantoprazole, omeprazole, metformin, simvastatin and prednisone, have an unknown severity rating.

Please also refer to the TGA-approved Product Information (PI) for full warnings and precautions.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a very high model score but no supporting clinical trials or literature (Evidence Level L5). The mechanistic link is speculative, because Ambras syndrome is not clearly androgen-driven. The drug is also teratogenic in male fetuses, which complicates use in a congenital condition.

To proceed, the following is needed:

Mechanism of action data confirming a rationale for TRPS1-related hypertrichosis
Preclinical or case-level evidence of any effect on hair growth in this condition
Review of the TGA Product Information for warnings and contraindications
A safety assessment for the relevant (likely paediatric) population
Consideration of better-supported hair-related targets, such as androgen-dependent conditions, before investing in this indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.